Literature DB >> 6519150

Comparison of plasma levels of canrenone and metabolites after base hydrolysis in young and elderly subjects following single and multiple doses of spironolactone.

P C Ho, D W Bourne, E J Triggs, B A Smithurst.   

Abstract

Plasma levels of canrenone and 'total metabolites' after base hydrolysis were compared in young and elderly subjects following single and multiple doses of spironolactone. After the initial dose on Day 1, plasma levels of canrenone and 'total metabolites' were higher in the young than in the elderly group, and significant differences were found between the two age groups in the AUC for both canrenone and 'total metabolites'. However, these differences between the two age groups diminished after multiple dosing on Day 8, and the steady state pre-dose plasma levels of canrenone and 'total metabolites' were significantly higher in the elderly subjects. The accumulation ratios of canrenone and 'total metabolites' were significantly higher in the elderly than in the young subjects. Both canrenone and canrenoic acid were extensively bound to plasma protein, but no differences were found between the two age groups in protein binding. Observed differences in plasma levels after single and multiple dosing between young and old subjects may be consequences of many factors such as a proportionate shift in metabolism with age; impaired oral absorption of the parent compound; and/or altered volume of distribution of the drug.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6519150     DOI: 10.1007/bf00549591

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  11 in total

Review 1.  Spironolactone: disposition, metabolism, pharmacodynamics, and bioavailability.

Authors:  A Karim
Journal:  Drug Metab Rev       Date:  1978       Impact factor: 4.518

Review 2.  Drug use in the elderly: a review of problems and special considerations.

Authors:  R E Vestal
Journal:  Drugs       Date:  1978-10       Impact factor: 9.546

Review 3.  Pharmacokinetic consequences of aging.

Authors:  D P Richey; A D Bender
Journal:  Annu Rev Pharmacol Toxicol       Date:  1977       Impact factor: 13.820

4.  Multiple dose kinetics of spironolactone and canrenoate-potassium in cardiac and hepatic failure.

Authors:  W Sadée; R Schröder; E von Leitner; M Dagcioglu
Journal:  Eur J Clin Pharmacol       Date:  1974       Impact factor: 2.953

5.  Fluorometric microassay for spironolactone and its metabolites in biological fluids.

Authors:  W Sadée; M Dagcioglu; S Riegelman
Journal:  J Pharm Sci       Date:  1972-07       Impact factor: 3.534

6.  Common pitfalls in geriatric drug prescribing.

Authors:  P G Shaw
Journal:  Drugs       Date:  1982-04       Impact factor: 9.546

7.  Distribution coefficients and in vitro human serum protein binding of spironolactone and its 7 alpha-carboxymethyl analog.

Authors:  A S Ng; R B Kluza; D W Newton
Journal:  J Pharm Sci       Date:  1980-01       Impact factor: 3.534

8.  Spironolactone. I. Disposition and metabolism.

Authors:  A Karim; J Zagarella; J Hribar; M Dooley
Journal:  Clin Pharmacol Ther       Date:  1976-02       Impact factor: 6.875

Review 9.  Pharmacokinetics in the elderly.

Authors:  J Crooks; K O'Malley; I H Stevenson
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

10.  Pharmacokinetics of canrenone and metabolites after base hydrolysis following single and multiple dose oral administration of spironolactone.

Authors:  P C Ho; D W Bourne; E J Triggs; V Heazlewood
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

View more
  6 in total

Review 1.  Age-related changes in protein binding of drugs: implications for therapy.

Authors:  M K Grandison; F D Boudinot
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

Review 2.  Cardiovascular drug therapy in elderly patients: specific age-related pharmacokinetic, pharmacodynamic and therapeutic considerations.

Authors:  Arduino A Mangoni
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 3.  Plasma protein binding of drugs in the elderly.

Authors:  S M Wallace; R K Verbeeck
Journal:  Clin Pharmacokinet       Date:  1987-01       Impact factor: 6.447

4.  Pannexin Channel Inhibition: An Evolving Target to Lower Blood Pressure?

Authors:  Sabine Huke
Journal:  Circ Res       Date:  2018-02-16       Impact factor: 17.367

Review 5.  The effect of respiratory disorders on clinical pharmacokinetic variables.

Authors:  A M Taburet; C Tollier; C Richard
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

Review 6.  Metabolites of antihypertensive drugs. An updated review of their clinical pharmacokinetic and therapeutic implications.

Authors:  A Ebihara; A Fujimura
Journal:  Clin Pharmacokinet       Date:  1991-11       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.